BioSpace News Archive

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary financial results for the quarter ended September 30, 2020.

Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today the topline results from its Hamster Challenge Study.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), today announced its recently acquired SciSafe division has been awarded a two year contract from a large pharmaceutical company for cold chain management and storage of COVID-19 vaccines.

Integral Molecular and Totient announce a partnership leveraging Integral Molecular’s Membrane Proteome Array (MPA) target identification technology to advance the discovery of antibodies for cancer therapy. Totient reconstructs antibodies from tertiary lymphoid structures (TLS), which are structures formed in tissues affected by aut

PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx cli

Wheeler Labs, a company founded by experienced biotech CEO Dr. Jesse McCool, will bring to market a non-invasive, direct-to-patient, at-home COVID-19 test. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005257/en/ Experienced biotech CEO Dr. Jesse McCool launches Wheeler Labs (Photo: Bu

The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP ® (Oxford Genome Anatomy Project) target discovery platform, is the latest in a series of collaborations that strengthens Boehringer Ingelheim’s position and leading assets in cancer immunology. INGELHEIM, Germany & OXFORD, En

NDA s ubmission is supported by positive data from two Phase 3 studies ( VANISH Program ) in women with vulvovaginal candidiasis (VVC) As a qualified infectious disease product (QIDP) , ibrexafungerp is expected to receive a 6-month priority review following NDA acceptance

Yale University Study Found No Association Between Child Care and the Spread of COVID-19 to Providers; Child Care Aware of America Provides Recommendations for Providers, Parents and Policymakers

Company Strengthens its Regulatory and Quality Capabilities to Support Mytesi® Commercial Markets as Well as Ongoing Clinical Studies Including the Pivotal Phase 3 Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy